Open AccessGlucagon is associated with NAFLD inflammatory progression in type 2 diabetes, not with NAFLD fibrotic progression
Author(s) -
Yuying Wang,
Zu-Yu Lin,
Heng Wan,
Wen Zhang,
Fangzhen Xia,
Yi Chen,
Xiaoman Chen,
Chiyu Wang,
Chi Chen,
Ningjian Wang,
Yingli Lu
Publication year - 2021
Publication title -
european journal of gastroenterology and hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.881
H-Index - 102
eISSN - 1473-5687
pISSN - 0954-691X
DOI - 10.1097/meg.0000000000002269
Subject(s) - medicine , nonalcoholic fatty liver disease , diabetes mellitus , metabolic syndrome , gastroenterology , type 2 diabetes , steatosis , cirrhosis , endocrinology , fibrosis , fatty liver , dyslipidemia , type 2 diabetes mellitus , insulin resistance , disease
Higher prevalence of progressive stages of nonalcoholic fatty liver disease (NAFLD) and hyperglucagonemia were observed in type 2 diabetes. We aim to investigate whether islet alpha cell dysfunction (evaluated by glucagon) associates with NAFLD progression in type 2 diabetic adults.